Heidi Sprang Email Address

Product Director, Taspoglutide

Akebia Therapeutics is a biopharmaceutical company and global leader in developing therapies using hypoxia inducible factor (HIF) to treat serious disease.

Strategic and collaborative biopharma leader with diverse US and international experience across marketing, managed care, and business development gained at large, medium, and small companies. Strong track record leading strategic initiatives across all stages of the lifecycle, including early stage, launch, and mature brands. Demonstrated ability to identify and resolve complex problems, interact with high level executive team, and work across global organizations. • Launched multiple new drugs, including first-in-class/first-in-disease, boxed warning, and REMS products. • Developed pricing and reimbursement strategies to optimize access and profitability across open and closed distribution models. • Assessed commercial opportunity and risk of individual product assets and company portfolios, including preparation of detailed P&L models, to support business development and investment recommendations. • Diverse therapeutic experience across oncology, pulmonary, immunology, cardiology, and metabolism, as well as primary care, specialty care, and orphan diseases. • Recruited and managed direct reports and successfully led numerous cross-functional project teams. • Recipient of multiple awards for commercial and marketing excellence.